You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

 

Online download statistics by month:

Online download statistics by month: December 2021 to September 2024

AbstractFullPdf
Dec 2021488492190
Jan 202222124169
Feb 202212413048
Mar 202210510653
Apr 2022757718
May 2022686836
Jun 2022818333
Jul 202212513147
Aug 20229910121
Sep 202215916246
Oct 202214614643
Nov 2022868954
Dec 2022979826
Jan 202310810929
Feb 2023868825
Mar 2023777837
Apr 2023555628
May 2023646952
Jun 202312112248
Jul 2023757534
Aug 2023969621
Sep 20239810240
Oct 2023535331
Nov 2023858526
Dec 2023525231
Jan 2024616228
Feb 2024575719
Mar 2024676979
Apr 2024616341
May 2024464321
Jun 2024414120
Jul 2024757435
Aug 2024424225
Sep 2024545534
Total334834151388